Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 57, 2606-2610, July 1, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Guvakova, M. A.
Right arrow Articles by Surmacz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Guvakova, M. A.
Right arrow Articles by Surmacz, E.

Tamoxifen Interferes with the Insulin-like Growth Factor I Receptor (IGF-IR) Signaling Pathway in Breast Cancer Cells1

Marina A. Guvakova and Ewa Surmacz2

Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

The insulin-like growth factor I receptor (IGF-IR) is involved in the control of breast cancer cell growth. The cytostatic activity of tamoxifen (Tam), a nonsteroidal antiestrogen, is partially mediated through interference with IGF-I-R-dependent proliferation, yet the effects of Tam on IGF-IR intracellular signaling have never been elucidated. Consequently, we investigated how Tam modifies the IGF-IR signaling pathway in estrogen receptor-positive MCF-7 breast cancer cells and in MCF-7-derived clones overexpressing either the IGF-IR (MCF-7/IGF-IR cells) or its major substrate, IRS-1 (MCF-7/IRS-1 cells). MCF-7/IGF-IR and MCF-7/IRS-1 cells exhibit greatly reduced estrogen growth requirements but retain estrogen receptors and express sensitivity to antiestrogens comparable to that in the parental cells. In all tested cell lines, regardless of the amplification of IGF signaling, a 4-day treatment with 10 nM Tam produced a similar cytostatic effect. In MCF-7 and MCF-7/IGF-IR cells, growth inhibition by Tam was associated with the reduced tyrosine phosphorylation of the IGF-IR in the presence of IGF-I; however, the basal level of the IGF-IR remained unaffected. Moreover, Tam inhibited both basal and IGF-I-induced tyrosine phosphorylation of IRS-1, which was accompanied by down-regulation of IRS-1-associated phosphatidylinositol 3'-kinase activity and reduced IRS-1/growth factor receptor-bound protein 2 (GRB2) binding. In contrast, under the same treatment, tyrosine phosphorylation of Src-homology/collagen proteins (SHC; another substrate of the IGF-IR) and SHC/GRB2 binding were elevated. The protein levels of the IGF-IR and IRS-1 were not modified by Tam, whereas SHC protein expression was either not affected or moderately decreased by the treatment.

In summary, this work provides the first evidence that in MCF-7 cells, cytostatic effects of Tam are associated with the modulation of IGF-IR signaling, specifically with: (a) down-regulation of IGF-I-induced tyrosine phosphorylation of the IGF-IR; (b) inhibition of IRS-1/phosphatidylinositol 3'-kinase signaling; and (c) up-regulation of SHC tyrosine phosphorylation and increased SHC/GRB2 binding. It is hypothesized that dephosphorylation of IRS-1 could be a major contributing factor in Tam cytostatic activity.

1 This work was supported in part by Grant DK 48969 from the NIH (to E. S.). E. S. is a recipient of Career Development Award DAMD 17-96-1-6250 from the Department of the Army.

2 To whom requests for reprints should be addressed, at Kimmel Cancer Institute BLSB 606A, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107. Phone: (215) 503-4512; Fax: (215) 923-0249.

Received 3/ 7/97. Accepted 5/13/97.




This article has been cited by other articles:


Home page
J. Clin. Pathol.Home page
D. Sisci, C. Morelli, C. Garofalo, F. Romeo, L. Morabito, F. Casaburi, E. Middea, S. Cascio, E. Brunelli, S. Ando, et al.
Expression of nuclear insulin receptor substrate 1 in breast cancer
J. Clin. Pathol., June 1, 2007; 60(6): 633 - 641.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. Hiscox, L Morgan, T. Green, and R. I Nicholson
Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S53 - S59.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. Van Den Bossche, S. Van Belle, F. De Winter, A. Signore, and C. Van de Wiele
Early Prediction of Endocrine Therapy Effect in Advanced Breast Cancer Patients Using 99mTc-Depreotide Scintigraphy
J. Nucl. Med., January 1, 2006; 47(1): 6 - 13.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
L-A Martin, S Pancholi, C M W Chan, I Farmer, C Kimberley, M Dowsett, and S R D Johnston
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
Endocr. Relat. Cancer, December 1, 2005; 12(4): 1017 - 1036.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson
Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor
Endocrinology, November 1, 2005; 146(11): 4609 - 4618.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J M Gee, J F Robertson, E Gutteridge, I O Ellis, S E Pinder, M Rubini, and R I Nicholson
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S99 - S111.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. H. Ibrahim and D. Yee
Insulin-Like Growth Factor-I and Breast Cancer Therapy
Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White, and L. M. Shaw
Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis
Mol. Cell. Biol., November 15, 2004; 24(22): 9726 - 9735.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Chen, E. Hui, T. Ip, and L. U. Thompson
Dietary Flaxseed Enhances the Inhibitory Effect of Tamoxifen on the Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) in Nude Mice
Clin. Cancer Res., November 15, 2004; 10(22): 7703 - 7711.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Garofalo, D. Sisci, and E. Surmacz
Leptin Interferes with the Effects of the Antiestrogen ICI 182,780 in MCF-7 Breast Cancer Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6466 - 6475.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Van Den Bossche and C. Van de Wiele
Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status
J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
W.-F. Chen and M.-S. Wong
Genistein Enhances Insulin-Like Growth Factor Signaling Pathway in Human Breast Cancer (MCF-7) Cells
J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2351 - 2359.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. I. Nicholson, I. R. Hutcheson, J. M. Knowlden, H. E. Jones, M. E. Harper, N. Jordan, S. E. Hiscox, D. Barrow, and J. M. W. Gee
Nonendocrine Pathways and Endocrine Resistance: Observations with Antiestrogens and Signal Transduction Inhibitors in Combination
Clin. Cancer Res., January 1, 2004; 10(1): 346S - 354S.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
D. B. Boyd
Insulin and Cancer
Integr Cancer Ther, December 1, 2003; 2(4): 315 - 329.
[Abstract] [PDF]


Home page
EndocrinologyHome page
J. M. W. Gee, M. E. Harper, I. R. Hutcheson, T. A. Madden, D. Barrow, J. M. Knowlden, R. A. McClelland, N. Jordan, A. E. Wakeling, and R. I. Nicholson
The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
Endocrinology, November 1, 2003; 144(11): 5105 - 5117.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. Yu, X.-O. Shu, B. D. L. Li, Q. Dai, Y.-T. Gao, F. Jin, and W. Zheng
Joint Effect of Insulin-like Growth Factors and Sex Steroids on Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 1067 - 1073.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M. B. Martin and A. Stoica
Insulin-Like Growth Factor-I and Estrogen Interactions in Breast Cancer
J. Nutr., December 1, 2002; 132(12): 3799S - 3801.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Bompard, C. Puech, C. Prebois, F. Vignon, and G. Freiss
Protein-tyrosine Phosphatase PTPL1/FAP-1 Triggers Apoptosis in Human Breast Cancer Cells
J. Biol. Chem., November 27, 2002; 277(49): 47861 - 47869.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Varma and S. E. Conrad
Antiestrogen ICI 182,780 Decreases Proliferation of Insulin-like Growth Factor I (IGF-I)-treated MCF-7 Cells without Inhibiting IGF-I Signaling
Cancer Res., July 15, 2002; 62(14): 3985 - 3991.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
R. I. NICHOLSON, I. R. HUTCHESON, M. E. HARPER, J. M. KNOWLDEN, D. BARROW, R. A. McCLELLAND, H. E. JONES, A. E. WAKELING, and J.M. W. GEE
Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer
Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 104 - 115.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Ko, G. R. Cardona, A. Henrion-Caude, and W. W. Chin
Identification and Characterization of a Tissue-Specific Coactivator, GT198, That Interacts with the DNA-Binding Domains of Nuclear Receptors
Mol. Cell. Biol., January 1, 2002; 22(1): 357 - 369.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Bartucci, C. Morelli, L. Mauro, S. Ando', and E. Surmacz
Differential Insulin-like Growth Factor I Receptor Signaling and Function in Estrogen Receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 Breast Cancer Cells
Cancer Res., September 1, 2001; 61(18): 6747 - 6754.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. M. Shaw
Identification of Insulin Receptor Substrate 1 (IRS-1) and IRS-2 as Signaling Intermediates in the {alpha}6{beta}4 Integrin-Dependent Activation of Phosphoinositide 3-OH Kinase and Promotion of Invasion
Mol. Cell. Biol., August 1, 2001; 21(15): 5082 - 5093.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Oesterreich, P. Zhang, R. L. Guler, X. Sun, E. M. Curran, W. V. Welshons, C. K. Osborne, and A. V. Lee
Re-expression of Estrogen Receptor {alpha} in Estrogen Receptor {alpha}-negative MCF-7 Cells Restores both Estrogen and Insulin-like Growth Factor-mediated Signaling and Growth
Cancer Res., August 1, 2001; 61(15): 5771 - 5777.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. T. Yu, R. G. Foster, and D. C. Dean
Transcriptional Repression by Rb-E2F and Regulation of Anchorage-Independent Survival
Mol. Cell. Biol., May 15, 2001; 21(10): 3325 - 3335.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
D. L. Hadsell, T. Alexeenko, Y. Klemintidis, D. Torres, and A. V. Lee
Inability of Overexpressed des(1-3)Human Insulin-Like Growth Factor I (IGF-I) to Inhibit Forced Mammary Gland Involution Is Associated with Decreased Expression of IGF Signaling Molecules
Endocrinology, April 1, 2001; 142(4): 1479 - 1488.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. Chiarenza, P. Lazarovici, L. Lempereur, G. Cantarella, A. Bianchi, and R. Bernardini
Tamoxifen Inhibits Nerve Growth Factor-induced Proliferation of the Human Breast Cancerous Cell Line MCF-7
Cancer Res., April 1, 2001; 61(7): 3002 - 3008.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
H. Yu and T. Rohan
Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression
J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Molloy, F. E. B. May, and B. R. Westley
Insulin Receptor Substrate-1 Expression Is Regulated by Estrogen in the MCF-7 Human Breast Cancer Cell Line
J. Biol. Chem., April 21, 2000; 275(17): 12565 - 12571.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Brinkman, S. van der Flier, E. M. Kok, and L. C. J. Dorssers
BCAR1, a Human Homologue of the Adapter Protein p130Cas, and Antiestrogen Resistance in Breast Cancer Cells
J Natl Cancer Inst, January 19, 2000; 92(2): 112 - 120.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Burtscher, A. Compagni, G. M. Lamm, and G. Christofori
An Insulin-like Growth Factor-mediated, Phosphatidylinositol 3' Kinase-independent Survival Signaling Pathway in {beta} Tumor Cells
Cancer Res., August 1, 1999; 59(16): 3923 - 3926.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. J. Rosen
Serum Insulin-like Growth Factors and Insulin-like Growth Factor-binding Proteins: Clinical Implications
Clin. Chem., August 1, 1999; 45(8): 1384 - 1390.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. V. Lee, J. G. Jackson, J. L. Gooch, S. G. Hilsenbeck, E. Coronado-Heinsohn, C. K. Osborne, and D. Yee
Enhancement of Insulin-Like Growth Factor Signaling in Human Breast Cancer: Estrogen Regulation of Insulin Receptor Substrate-1 Expression in Vitro and in Vivo
Mol. Endocrinol., May 1, 1999; 13(5): 787 - 796.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
Z.-D. Xu, L. Oey, S. Mohan, M. H. Kawachi, N.-S. Lee, J. J. Rossi, and Y. Fujita-Yamaguchi
Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid in Vitro and in Prostate Cancer Cells
Endocrinology, May 1, 1999; 140(5): 2134 - 2144.
[Abstract] [Full Text]


Home page
Mol. Endocrinol.Home page
G. Freiss, C. Puech, and F. Vignon
Extinction of Insulin-Like Growth Factor-I Mitogenic Signaling by Antiestrogen-Stimulated Fas-Associated Protein Tyrosine Phosphatase-1 in Human Breast Cancer Cells
Mol. Endocrinol., April 1, 1998; 12(4): 568 - 579.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
A. Lai, B. Sarcevic, O. W. J. Prall, and R. L. Sutherland
Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1
J. Biol. Chem., July 6, 2001; 276(28): 25823 - 25833.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.